Abstract

Neurodegenerative disorders and cancer, though seemingly disparate, share underlying cellular and molecular mechanisms, including aberrant cell proliferation and programmed cell death. This convergence provides a unique opportunity for medication repurposing, where existing anticancer drugs may find a new role in mitigating neurodegenerative diseases. This review explores the potential of repurposing anticancer drugs as a novel therapeutic approach for neurodegenerative disorders. We delve into the commonalities between these seemingly distinct pathologies and discuss the promise, challenges, and future directions in harnessing the anticancer potential for neuroprotection.